RxDoctor Payments DataLook up a doctor →

Deborah Horn, DO

Adult Medicine · Bellaire, TXNPI 1437202355

Payments from drug & device makers

$2,385,373in general payments, 2019–2025

Across 608 payments — averaging $3923.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.7M
  • Novo Nordisk$468K
  • Novo Nordisk AS$106K
  • Lilly USA, LLC$54K
  • Boehringer Ingelheim$17K
  • Amgen$10K
  • plus $24K from 13 others
$56,245in research payments, 2019–2025

Across 31 payments — averaging $1814.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$53K
  • Eli Lilly$4K

What the payments were for

  • Consulting fees$327,75145%
  • Speaking & faculty fees$261,70036%
  • Travel & lodging$115,44516%
  • Food & beverage$18,3783%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,385,373 in reported general payments places this provider in the 95th percentile of 98 adult medicine providers in Texas.

See all adult medicine providers in Texas

Medicare billing

Part B allowed, 2024
$7,766
Medicare patients
31
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$75,302
MounjaroTirzepatide46$55,687
Metformin Hcl ErMetformin Hcl39$860
Bupropion XlBupropion Hcl11$259
Topiramate36$234
Metformin Hcl26$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$467,647$75,30268 claims
Lilly USA, LLCMounjaro$53,887$55,68746 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 adult medicine providers in Texas.

Other adult medicine in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →